Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Silva Stoughton"'
Autor:
John Doukas, Xianchang Gong, Andrew McPherson, Suhan Tang, Glenn Noronha, Tessa Brodhag, Daniel L. Lohse, Antonio Boccia, Moorthy S. S. Palanki, Ehab Y. Hanna, Hong Gu, Kathy Barrett, Colleen Gritzen, Shiyin Yee, Hong Zhu, Ningning Zhao, Chi Ching Mak, Elena Dneprovskaia, Ute Splittgerber, Chun P. Chow, Ge Li, Richard E. Fine, Jianguo Cao, Feng Shi, Richard Soll, Xinshan Kang, Steven Hu, Silva Stoughton, Jann Key, Ved P. Pathak, Binqi Zeng, Ahmed A Kousba, John Hood, Boris Klebansky, Joel Renick
Publikováno v:
Bioorganicmedicinal chemistry letters. 17(3)
We describe the identification of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine (3), a potent, orally active Src inhibitor with desirable PK properties, demonstrated activity in human tumor cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c457d51e7ad2328a70dfc66c65cdf94c
https://pubmed.ncbi.nlm.nih.gov/17113292
https://pubmed.ncbi.nlm.nih.gov/17113292
Autor:
Catriona Jamieson, Marcela Alomia, John Doukas, Glenn Noronha, Michael D. Martin, Cyrus Virata, Daniel L. Lohse, John Hood, Betty Tam, Ehab Y. Hanna, Chi Ching Mak, Silva Stoughton, Richard Soll
Publikováno v:
Blood. 110:898-898
A number of genetic mutations have been identified in the development of acute myeloid leukemia (AML), including mutations in the proto-oncogene N-RAS, p53, c-Kit and the FMS-like receptor tyrosine kinase 3 (FLT3). FLT3 plays an important role in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5de2146c14417b86eb4e1005bd78ce16
https://doi.org/10.1182/blood.v110.11.898.898
https://doi.org/10.1182/blood.v110.11.898.898
Autor:
Elena Dneprovskaia, Ved P. Pathak, Chi-Ching Mak, Kathy Barrett, Binqi Zeng, Richard M. Soll, Daniel L. Lohse, Andy McPherson, Joe Renick, John Hood, Glenn Noronha, Hong Zhu, Ehab Y. Hanna, Jon Cao, Silva Stoughton, Linda Hwang, Betty Y. Y. Tam, Moorthy S. S. Palanki, Chun Chow
Publikováno v:
Blood. 108:2182-2182
The T315I point mutation situated at the ATP-binding site of BCR/ABL tyrosine kinase remains to be the major unmet medical need in treating CML patients. None of the marketed CML drugs, including Imatinib or the recently approved Dasatinib, are able
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54086744ee7edc814cd3ce9d7b2d22e7
https://doi.org/10.1182/blood.v108.11.2182.2182
https://doi.org/10.1182/blood.v108.11.2182.2182